Halozyme Therapeutics vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Halozyme Therapeutics Inc (HALO)

Q3 202615 Jul – 8 Oct 2026

▲3▼1

Halozyme Q3: Strong Earnings, New Deals, Legal Win, But Dilution Risk

Q2 Earnings Beat and Guidance Raise Halozyme reported Q2 revenue of $481 million, up 48% from a year earlier, and raised its full-year guidance. The stock hit a 52-week high as investors cheered the strong results and brighter outlook.
This is the core financial performance that directly drove the stock higher during the quarter.
New ENHANZE Partnerships and Expanded Collaboration Halozyme signed new ENHANZE deals with Incyte, Vertex, and GSK, and expanded its existing collaboration with argenx. These agreements broaden future royalty streams, giving investors more confidence in long-term revenue growth.
New partnerships are a key growth driver and were a major positive catalyst during the quarter.
Legal Win and Positive Trial Data A Dutch court blocked Merck’s subcutaneous Keytruda for patent infringement, potentially adding royalties or damages for Halozyme. Also, positive Darzalex Faspro trial data support long-term royalties, reinforcing the company’s intellectual property strength.
These legal and clinical developments protect and enhance future revenue streams, directly impacting investor sentiment.
Convertible Notes Raise Creates Dilution Risk Halozyme raised $1.3 billion in convertible notes, strengthening its balance sheet but potentially diluting shares if the stock price rises above the conversion price. This is a risk that could weigh on the stock if not managed carefully.
This is a significant counterweight to the positive news, as dilution can pressure the stock price.

September 202615 Aug – 8 Oct 2026

▲3

Halozyme's Royalty Engine Roars as Legal Wins and Deals Pile Up

Q2 Beat and Raised Guidance Halozyme's Q2 revenue jumped 48% to $481 million, beating estimates, and the company raised full-year guidance. This shows its royalty business is growing faster than expected, which directly boosts investor confidence and the stock price.
This is the core fundamental driver of the stock's recent surge and answers why HALO is moving.
New ENHANZE Deals Expand Royalty Stream Halozyme signed five new collaborations, including with Vertex, GSK, and Incyte, and expanded its argenx deal from six to eight targets. More partners mean more future milestone payments and royalties, which supports long-term revenue growth and lifts the stock.
New deals are a key growth catalyst that directly increases future royalty revenue.
Dutch Court Blocks Merck's Keytruda SC A Dutch court ruled that Merck's subcutaneous Keytruda infringes Halozyme's patent, banning sales in eight European markets. This legal win protects Halozyme's technology and could lead to royalties or damages from Merck, boosting the stock.
This is a major legal victory that validates Halozyme's patent portfolio and could unlock significant value.
Upsized Convertible Notes Offering Halozyme raised $1.3 billion in convertible notes to refinance older debt. While this strengthens the balance sheet and funds growth, it also creates potential future dilution if the stock rises above the conversion price, which can weigh on shares.
This financing event affects the capital structure and has both positive and negative implications for the stock.

Latest15 Aug – 8 Oct 2026

▲3

Halozyme's Royalty Engine Roars as Legal Wins and Deals Pile Up

Q2 Beat and Raised Guidance Halozyme's Q2 revenue jumped 48% to $481 million, beating estimates, and the company raised full-year guidance. This shows its royalty business is growing faster than expected, which directly boosts investor confidence and the stock price.
This is the core fundamental driver of the stock's recent surge and answers why HALO is moving.
New ENHANZE Deals Expand Royalty Stream Halozyme signed five new collaborations, including with Vertex, GSK, and Incyte, and expanded its argenx deal from six to eight targets. More partners mean more future milestone payments and royalties, which supports long-term revenue growth and lifts the stock.
New deals are a key growth catalyst that directly increases future royalty revenue.
Dutch Court Blocks Merck's Keytruda SC A Dutch court ruled that Merck's subcutaneous Keytruda infringes Halozyme's patent, banning sales in eight European markets. This legal win protects Halozyme's technology and could lead to royalties or damages from Merck, boosting the stock.
This is a major legal victory that validates Halozyme's patent portfolio and could unlock significant value.
Upsized Convertible Notes Offering Halozyme raised $1.3 billion in convertible notes to refinance older debt. While this strengthens the balance sheet and funds growth, it also creates potential future dilution if the stock rises above the conversion price, which can weigh on shares.
This financing event affects the capital structure and has both positive and negative implications for the stock.

July 202615 Jul – 14 Aug 2026

▲4

Halozyme's Q2 Beat and New Incyte Deal Drive Growth Story

Q2 earnings beat and raised guidance Halozyme reported Q2 revenue of $481 million, up 48% from a year ago, and raised its full-year revenue outlook to $1.835–$1.910 billion. The stock jumped 20% on the news, as investors saw stronger demand for its drug-delivery technology and better profit potential.
This is the biggest new financial event, directly boosting investor confidence and the stock price.
New Incyte collaboration for ENHANZE Halozyme signed a global licensing deal with Incyte to use its ENHANZE technology with an experimental cancer drug. Halozyme gets upfront cash, potential milestone payments, and future royalties. This expands its partner base and adds a new stream of income without major new spending.
This is a fresh partnership that adds future revenue and validates Halozyme's technology platform.
Positive trial results for Darzalex Faspro A late-stage trial showed that Darzalex Faspro, which uses Halozyme's ENHANZE technology, combined with J&J's Talvey significantly improved survival in multiple myeloma patients. This supports continued adoption of the drug, meaning more royalties for Halozyme over time.
It reinforces demand for an existing partnered product, which drives recurring royalty revenue.
Stock hits 52-week high on momentum Halozyme shares reached a 52-week high of $103.30 after the strong earnings and guidance. The stock has risen 46% over the past year, reflecting growing investor confidence in its business model and cash generation.
This captures the market's positive reaction and momentum, which can attract more investors.

15 Jul – 14 Aug 2026

▲4

Halozyme's Q2 Beat and New Incyte Deal Drive Growth Story

Q2 earnings beat and raised guidance Halozyme reported Q2 revenue of $481 million, up 48% from a year ago, and raised its full-year revenue outlook to $1.835–$1.910 billion. The stock jumped 20% on the news, as investors saw stronger demand for its drug-delivery technology and better profit potential.
This is the biggest new financial event, directly boosting investor confidence and the stock price.
New Incyte collaboration for ENHANZE Halozyme signed a global licensing deal with Incyte to use its ENHANZE technology with an experimental cancer drug. Halozyme gets upfront cash, potential milestone payments, and future royalties. This expands its partner base and adds a new stream of income without major new spending.
This is a fresh partnership that adds future revenue and validates Halozyme's technology platform.
Positive trial results for Darzalex Faspro A late-stage trial showed that Darzalex Faspro, which uses Halozyme's ENHANZE technology, combined with J&J's Talvey significantly improved survival in multiple myeloma patients. This supports continued adoption of the drug, meaning more royalties for Halozyme over time.
It reinforces demand for an existing partnered product, which drives recurring royalty revenue.
Stock hits 52-week high on momentum Halozyme shares reached a 52-week high of $103.30 after the strong earnings and guidance. The stock has risen 46% over the past year, reflecting growing investor confidence in its business model and cash generation.
This captures the market's positive reaction and momentum, which can attract more investors.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.